Can cholesterol-lowering medicine make radiation more effective at curing prostate cancer?

October 29, 2007

Patients with prostate cancer who receive high-dose radiation treatment and also take statin drugs commonly used to lower cholesterol have a 10 percent higher chance of being cured of their cancer at 10 years after diagnosis (76 percent), compared to those who don't take these medications (66 percent), according to a study presented at a scientific session October 31, 2007, at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.

The study demonstrated that the greatest benefit of statin medications was observed in patients who had more aggressive or advanced forms of prostate cancer. The research also showed that men who took statins during high-dose radiation therapy had a lower rate of the cancer spreading to distant parts of the body. "We were, indeed, surprised by the findings that statins used by these patients for other conditions was shown to improve the effectiveness of radiation treatment in killing prostate cancer cells," said Michael J. Zelefsky, M.D., the senior author of the study and a radiation oncologist at Memorial Sloan-Kettering Cancer Center in New York. "The use of statins during radiation may also be effective in the treatment of other types of cancer. However, more studies are necessary to explore the association between statins and radiation treatment in curing cancers."

The retrospective study involved nearly 900 men treated with high-dose radiation therapy for prostate cancer, some of whom were also taking statin drugs, from January 1995 to July 2000. Statins are a class of drugs used to lower the cholesterol level in people with or at risk of cardiovascular disease.
-end-
For more information on treatments for prostate cancer, visit www.rtanswers.org. The abstract, "Statin Use and Clinical Outcomes after High Dose Radiotherapy for Prostate Cancer," will be presented in a scientific session from 1:00 - 2:30 p.m., Wednesday, October 31, 2007. To speak to the senior study author, Michael J. Zelefsky, M.D., please call Beth Bukata or Nicole Napoli October 28-31, 2007, in the ASTRO Press Room at the Los Angeles Convention Center at 213-743-6222 or 213-743-6223. You may also e-mail them at bethb@astro.org or nicolen@astro.org.

American Society for Radiation Oncology

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.